A detailed history of Clearstead Advisors, LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Clearstead Advisors, LLC holds 63 shares of BPMC stock, worth $5,698. This represents 0.0% of its overall portfolio holdings.

Number of Shares
63
Previous 98 35.71%
Holding current value
$5,698
Previous $10,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$84.1 - $120.5 $2,943 - $4,217
-35 Reduced 35.71%
63 $5,000
Q2 2024

Aug 09, 2024

BUY
$85.18 - $108.78 $8,347 - $10,660
98 New
98 $10,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.4B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Clearstead Advisors, LLC Portfolio

Follow Clearstead Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Clearstead Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Clearstead Advisors, LLC with notifications on news.